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Abstract: After nearly 20 years of research on the use of ruthenium in the fight against cancer,
only two Ru(III) coordination complexes have advanced to clinical trials. During this time, the field
has produced excellent candidate drugs with outstanding in vivo and in vitro activity; however,
we have yet to find a ruthenium complex that would be a viable alternative to platinum drugs
currently used in the clinic. We aimed to explore what we have learned from the most prominent
complexes in the area, and to challenge new concepts in chemical design. Particularly relevant
are studies involving NKP1339, NAMI-A, RM175, and RAPTA-C, which have paved the way for
current research. We explored the development of the ruthenium anticancer field considering that
the mechanism of action of complexes no longer focuses solely on DNA interactions, but explores a
diverse range of cellular targets involving multiple chemical strategies.
Keywords: ruthenium; anticancer; metal complex
1. Introduction
Cancer is a major health burden in the developed world. Although many breakthroughs in
biological targeted approaches have occurred (specifically, immunological therapy), an unmet clinical
need remains for a large section of the patient population, so wide-spectrum chemotherapy agents are
still required. This space is currently addressed with the use of platinum(II) coordination complexes,
namely Cisplatin (CDDP), Oxaliplatin and Carboplatin (worldwide approval), alongside Nedaplatin
and Lobaplatin, which are restricted to selected markets. Such platinum agents lack cellular selectivity,
so rapidly proliferating cells (hair follicles, bone marrow, and gastrointestinal tract) are particularly
vulnerable to off-target effects. This lack of cellular selectivity can lead to the development of severe
side effects not limited to nausea, vomiting, hair loss, nephrotoxicity, neurotoxicity, and hearing
loss [1,2].
The prevalence of platinum resistance in the clinic, both intrinsic and acquired [3–5], is an
escalating clinical concern, especially considering that platinum drugs are currently used in over
half of all chemotherapy regimens [3]. This has sparked the development of a new generation of
cytotoxics based on different metals, and corresponding coordination complexes, which excel in
cellular selectivity and retain their use against a wide range of malignancies, while exhibiting unique
mechanism(s) of action. Given the chemical similarity of the platinum group of metals (Pt, Pd, Rh, Ir,
Ru, and Os), given the successes of platinum therapies, interest in ruthenium(II/III) complexes has
increased considerably.
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2. Ruthenium Complexes as Anticancer Agents
Ruthenium compounds have been proven to be a starting point in the search for alternatives
to platinum drugs in the clinic, as these compounds have both comparable ligand exchange kinetics
and a greater number of accessible coordination geometries. Such comparison considers that Pt(II)
compounds are limited to square planar geometries, akin to cisplatin, and that octahedral geometries
comparable to ruthenium complexes can be only be achieved by a higher oxidation state, e.g.,
Pt(IV). The investigation around such complexes has been intense, with highly-renowned and
international-leading research groups pouring resources into this fast growing field. The chemistry of
Ru(II) and Ru(III) complexes is well established in both the materials and medicinal chemistry fields,
and research into their use as prospective anticancer agents is widely spread. The latter oxidation state
complexes are typically considered to be more inert, which is, to some extent, attributable to the higher
effective nuclear charge. In combination with the highly reducing environment of a cancer cell, an
“activation by reduction” mechanism has been speculated for many Ru(III) complexes [6], which are
reduced to their more active Ru(II) form by cellular reductants such as ascorbate [7].
The in-cell mechanism of action (MoA) for many ruthenium complexes differs from the
DNA-binding mechanism typically associated with platinum drugs [8]. With a wider range of
intracellular targets, ruthenium anticancer complexes are well established, and many examples have
shown promise in chemical model systems, in vitro, and in vivo [9–11]. However, despite widespread
efforts, only three ruthenium complexes (NKP1339, NAMI-A, and TLD1433) have reached clinical
trials. NKP1339, and NAMI-A are both being developed as chemotherapeutic agents, while octahedral
Ru(II) complex TLD1433 has potential as a photosensitizer for photo-dynamic therapy [12]. Research
into future anticancer agents should learn from both successes and difficulties encountered during the
development of previous complexes in order to identify desirable physical, chemical, and biological
properties associated with a successful future Ru drug candidate.
In this review, we critically evaluate four of the most significant Ru coordination complexes,
NAMI-A, NKP1339, RM175, and RAPTA-C, and assess their contribution to the advancement of
future ruthenium-based anticancer agents.
3. Case Study: RM175
RM175 [Ru(biphenyl)Cl(en)]+, where en = 1,2-ethylenediamine, was amongst the first
ruthenium(II) complexes to be explored for anticancer activity (Figure 1). This pseudo-octahedral
organometallic complex was developed by the Sadler group in 2001 [13]. RM175 is comprised of
monodentate (chloride), bidentate (diamine), and arene (biphenyl) ligands, typical of a 3-legged
“piano-stool” geometry. Originally synthesized with the aim of targeting DNA, it is intended to take
advantage of the lower 2+ oxidation state that would not require activation by cellular reduction [14].
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pathways to assist in the modulation of cell growth and angiogenesis [21]. MMPs facilitate the 
migration and invasion of cancerous cells, through degradation of the extracellular matrix (ECM), 
suppression of the adaptive immune system, and other processes that promote cell survival and 
protect malignant cells from apoptosis [21,22]. Apoptosis, as a form of programmed cell death, does 
not procure an inflammatory response in principle; thus, MMPs are a noteworthy target for 
anticancer agents [23]. 
RM175 also exerts activity by disrupting the processes of cell invasion and migration. In order 
to assess the effect of metallodrugs on cellular detachment and re-adhesion, several proteins have 
been investigated including collagen IV, fibronectin, and poly-L-lysine. All these proteins may come 
into contact with malignant cells in vivo, since poly-L-lysine attracts cells through electrostatic 
interactions, and both fibronectin and collagen IV are constituents of the extracellular matrix. Upon 
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detachment from either fibronectin or poly-L-lysine, depending on the substance on which the cells 
were originally grown. This effect was absent in non-tumorigenic and non-invasive cell lines (HBL-
100 and MCF-7, respectively), suggesting that the reduction in cellular detachment after exposure to 
RM175 was selective for invasive cells that would otherwise metastasize. Adherence to cellular 
components is a vital stage in the formation of metastases, so the Ru(II) complex has the potential to 
expand this selective action across other cell lines. RM175 significantly inhibits cellular contact-
induced movement (haptotaxis) in MDA-MB231 and HLB-100 cells, preventing metastatic formation 
induced by this stimulus [14].  
The described effects on cell invasion and migration explain why the use of RM175 was directed 
toward preventing and treating metastases as opposed to the reduction in primary tumor volume. 
Though in vivo studies demonstrated a 50% reduction in primary mammary carcinoma (MCa) tumor 
mass, upon withdrawal of RM175, tumor growth resumed, demonstrating the limited effect of 
RM175 on primary tumors. MCa cells are also liable to spontaneously spread to lung tissue; therefore, 
the anti-metastatic activity was also assessed. The ruthenium complex was found to have greater 
potency against metastases over primary tumors, and the size of the administered dose was found to 
significantly impact the extent of metastatic growth. Although a high dose (10 mg/kg/day) resulted 
in an 85–95% reduction in metastatic mass, only 70% reduction was achieved at a lower dosage (7.5 
mg/kg/day). Supplementation of the dose with human serum albumin (HSA) in ratios from 1:1 to 
1:10 were found to elevate the drug’s cytotoxic profile and reduce cell viability to a greater extent, 
indicating that efficacy of RM175 may be greater in vivo than in vitro [14].  
RM175 has been reported to up-regulate the tumor suppressor p53 and the pro-apoptotic protein 
Bax in HCT-116-wt cells, contributing to apoptosis. Significant apoptosis only occurred in cells that 
were not p53/Bax-null, demonstrating that both proteins are vital for early RM175-induced apoptosis 
Figure 1. RM175 (left) and RAPTA-C (right) are typical examples of 18-el ctron ruthenium arene
“piano-stool” complexes, in which an η6-arene ring stabilises the 2+ oxidation state of the ruthenium
metal centre.
The arene substituent provides a hydrophobic surface, allowing for cellular diffusion through the
lipophilic plasma membrane [14]. After entry into the cell, but prior to binding with DNA, complex
activation is thought to occur by ligand exchange at the monodentate site [15,16]. The complex’s
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design envisaged the halogen atom acting like a leaving group, drawing similarities with the activation
of cisplatin. The aquation reaction would then generate a coordinative vacancy, which, in turn,
would allow for covalent binding to the N7 of guanine in the DNA double helix [14]. Although
Ru(II) complexes are known to bind to the guanine residues in DNA [17], it is thought that the
extended arene in this complex enables hydrophobic interactions to occur between RM175 and DNA
via arene-intercalation between base pairs [18]. As a consequence of the free rotation of biphenyl about
the Ru(II) centre, the structure is relatively flexible, which is anticipated to limit steric hindrance and
increase the complex’s DNA-binding affinity [19]. Conformational flexibility may allow the complex
to intercalate into the base pairs and bind to guanine simultaneously, as has been shown possible with
other ruthenium complexes [19]. This may explain why the resulting RM175-DNA adduct is more
resistant to DNA repair than platinated DNA; therefore, such observation begins to explain the lack of
cross-resistance with platinum [20].
Further biological studies into the mechanism of action of RM175 revealed new cellular targets
in addition to DNA binding, most notably the inhibition of matrix metalloproteinase-2 (MMP-2) [14].
MMPs are the most important members of the metalloproteinase family that contribute to tumor
progression. They govern the conditions of the tumor microenvironment and use signalling pathways
to assist in the modulation of cell growth and angiogenesis [21]. MMPs facilitate the migration and
invasion of cancerous cells, through degradation of the extracellular matrix (ECM), suppression of
the adaptive immune system, and other processes that promote cell survival and protect malignant
cells from apoptosis [21,22]. Apoptosis, as a form of programmed cell death, does not procure an
inflammatory response in principle; thus, MMPs are a noteworthy target for anticancer agents [23].
RM175 also exerts activity by disrupting the processes of cell invasion and migration. In order to
assess the effect of metallodrugs on cellular detachment and re-adhesion, several proteins have been
investigated including collagen IV, fibronectin, and poly-L-lysine. All these proteins may come into
contact with malignant cells in vivo, since poly-L-lysine attracts cells through electrostatic interactions,
and both fibronectin and collagen IV are constituents of the extracellular matrix. Upon exposure to
RM175, invasive MDA-MB-231 breast adenocarcinoma cells became more resistant to detachment
from either fibronectin or poly-L-lysine, depending on the substance on which the cells were originally
grown. This effect was absent in non-tumorigenic and non-invasive cell lines (HBL-100 and MCF-7,
respectively), suggesting that the reduction in cellular detachment after exposure to RM175 was
selective for invasive cells that would otherwise metastasize. Adherence to cellular components is
a vital stage in the formation of metastases, so the Ru(II) complex has the potential to expand this
selective action across other cell lines. RM175 significantly inhibits cellular contact-induced movement
(haptotaxis) in MDA-MB231 and HLB-100 cells, preventing metastatic formation induced by this
stimulus [14].
The described effects on cell invasion and migration explain why the use of RM175 was directed
toward preventing and treating metastases as opposed to the reduction in primary tumor volume.
Though in vivo studies demonstrated a 50% reduction in primary mammary carcinoma (MCa) tumor
mass, upon withdrawal of RM175, tumor growth resumed, demonstrating the limited effect of RM175
on primary tumors. MCa cells are also liable to spontaneously spread to lung tissue; therefore,
the anti-metastatic activity was also assessed. The ruthenium complex was found to have greater
potency against metastases over primary tumors, and the size of the administered dose was found to
significantly impact the extent of metastatic growth. Although a high dose (10 mg/kg/day) resulted
in an 85–95% reduction in metastatic mass, only 70% reduction was achieved at a lower dosage
(7.5 mg/kg/day). Supplementation of the dose with human serum albumin (HSA) in ratios from 1:1
to 1:10 were found to elevate the drug’s cytotoxic profile and reduce cell viability to a greater extent,
indicating that efficacy of RM175 may be greater in vivo than in vitro [14].
RM175 has been reported to up-regulate the tumor suppressor p53 and the pro-apoptotic protein
Bax in HCT-116-wt cells, contributing to apoptosis. Significant apoptosis only occurred in cells that
were not p53/Bax-null, demonstrating that both proteins are vital for early RM175-induced apoptosis
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(<48 h). Treatment with RM175 also induced long-term loss of cellular replication, independent of p53,
p21 waf1/Cip1, and Bax [17].
RM175 also induces G1/G2-phase cell cycle arrest in vitro [17]. G1 inhibition of cell cycle
progression was found to be dependent on tumor suppressors and cell cycle regulators, p53 and
p21, which binds to CDK1, as well as to, CDK2 [24], yet independent from the Bcl-2 family member,
Bax [17]. This highlights the vital role of both tumor suppressors in initiating cell cycle arrest in
contrast to RM175-mediated apoptosis, which only requires p53 and Bax. Exposure resulted in the
accumulation of the aforementioned genetic components [17], particularly p21, as expression of this
cell cycle regulator typically leads to cell cycle arrest [25]. Activation of p53 initiates a cascade of
anti-mitogenic signals, promoting the p21-induced inhibition of CDK2 activity. This consequently
prevents expression of various genes (some of which are involved in DNA replication) [25] and
inhibits progression to S phase. Alternatively, the cell cycle arrest in the G2 phase could be attributed
to p53-mediated activation of either the GADD45 protein or p21 [24], both of which inhibit CDK1,
thereby inducing G2/M cell cycle arrest [26]. RM175 exerts its anticancer activity by both preventing
progression through the cell cycle leading to apoptosis, and “traditional” disruption of DNA replication
by strand intercalation and nucleobase binding.
4. Case Study: RAPTA-C
A second notable piano-stool complex is RAPTA-C, a ruthenium(II) arene complex developed
by the Dyson group that comprises an amphiphilic 1,3,5-triaza-7-phosphaadamantane (PTA) ligand
and two labile chloride ligands additional to the η6-coordinated arene, which helps to stabilize the
+2 oxidation state (Figure 1) [27]. In contrast to other phosphine ligands [28], PTA is relatively
sterically undemanding and is anticipated to contribute to the increased water solubility of RAPTA-C
relative to other Ru(II) arene complexes [29]. Similarly to cisplatin, RAPTA-C undergoes rapid
hydrolysis of Ru–Cl at low (intracellular) chloride concentrations (4–5 mM), predominantly yielding
the mono-aquated complex, [Ru(p-cymene)Cl(H2O)(PTA)]+. The Ru–Cl bond remains intact at higher
chloride concentrations (100 mM, i.e., in blood) and, like cisplatin, RAPTA-C may be considered a
pro-drug in its di-chlorido form [28]. Initial studies of RAPTA-C indicated that damage to supercoiled
pBR322 DNA was pH-dependent (occurring only below physiological pH; <7.0), so it was hypothesized
that this may invoke selective targeting of the typically more acidic environment of cancer cells [27].
Unlike cisplatin, preliminary in vitro studies found RAPTA-C to be remarkably inactive toward
TS/A adenocarcinoma and non-cancerous epithelial (HBL-100) cell lines, as well as initially having
limited activity against primary tumors in vivo. However, later in vivo studies using pre-clinical
models (using chicken chorioallantoic membrane and, more recently, mice) found that RAPTA-C
was able to inhibit tumor growth by 50–75% [30,31]. In both instances, analysis of the treated tumor
identified the significant anti-angiogenic properties of the complex. Both RAPTA-C and structurally
similar RAPTA-B (in which the arene unit has been changed to a benzene ring) showed promise for
size reduction of solid lung metastases in vivo [30]. These pre-clinical studies clearly demonstrate
the requirement for careful optimization and control of experimental conditions, and for scientists
to be mindful of the fact that in vitro experiments often do not accurately predict in vivo activities.
Complexes, such as RAPTA-B or HC11, that contain cyclic, non-substituted hydrocarbons in their
structure have the potential to cause liver toxicity after P450 poly-hydroxylation; hence, in vivo
experiments need to closely monitor phase I metabolism of the ruthenium drugs [32]. In the case
of RAPTA complexes, even at the highest dose administered to mice, negligible side effects were
observed. Ruthenium was found to be excreted rapidly via the renal system and did not significantly
accumulate in vital organs [28,33].
Later structural iterations of RAPTA-C included tethering of organic substituents on the
coordinated arene. Planar anthracene groups were investigated to enhance DNA interaction by
intercalation with concurrent fluorescence to map intracellular localization, with limited success [34–36].
In contrast, similar naphthalimide (a DNA intercalator) complexes were found to possess modest
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potencies against A2780 ovarian cancer cells (and a platinum-resistant-derived cell line, A2780Cis)
(IC50 2.3–9.1 µM) and displayed some selectivity over non-cancerous (HEK-293) cells [37]. Conjugation
of ethacrynic acid, a glutathione transferase inhibitor, to RAPTA-C yielded a new ruthenium complex
that was found to bind to the enzyme’s H-site. Importantly, the ruthenium center is involved in
the inhibition of glutathione transferase through cysteine residue binding [38]. After an extended
incubation time, the ethacrynic acid moiety remained in the H-site of the enzyme but the ruthenium
center had been released, which was also found to occur in vitro [39,40].
Most recently, a comparative metallomic study of the metabolism of RAPTA-C and cisplatin was
reported. Despite RAPTA-C and cisplatin having similar labile chloride ligands with comparable
exchange kinetics, RAPTA-C was found to be more inert to extracellular reactions despite being
administered at a dose 40-fold higher than cisplatin. RAPTA-C was found to predominantly bind
albumin, though extracellular metal speciation was found to be time-dependent [41]. This highlights
the need to better understand speciation, and consequently drug pharmacokinetics and dynamics,
to form a well-rounded pre-clinical research portfolio.
Various combination therapies involving RAPTA-C have also been explored in vivo. When
administered alongside erlotinib (epidermal growth factor receptor (EGFR) inhibitor) and BEZ-235
(Phosphoinositide 3-kinase PI3K/mTOR inhibitor), the combination was found to synergistically
inhibit tumor growth (up to 11-fold relative to single-drug experiments) [42]. An alternative
combination therapy involving RAPTA-C and axitinib (vascular endothelial growth factor receptor
(VEGFR) targeting tyrosine kinase inhibitor) led to a ca. 90% inhibition of tumor growth with a dose of
only 0.4 mg/kg, despite negligible toxicity observed at doses of 100 mg/kg [43].
5. Case Study: NAMI-A
NAMI-A, originally synthesized by the groups of Alessio and Sava (Figure 2), differs from the
two previously described complexes, being composed of chloride, imidazole, and dimethylsulfoxide
(DMSO) in an octahedral arrangement around a Ru(III) center. Ruthenium(III) complexes are
often considered to be pro-drugs, since they are typically less reactive than Ru(II) congeners and
require activation via reduction to the 2+ oxidation state [44,45]. Such activation improves tumor
targeting as the hypoxic cellular environment favors reduction of the metal center, thereby generating
antiproliferative selectivity for cancerous cells compared to healthy cells [45,46]. Reduction of
ruthenium from +3 to +2 also leads to kinetic lability; hence, the hydrolysis of chlorido ligands
occurs at a faster rate, which may facilitate the reaction of ruthenium complexes with DNA [47].
In highly reactive cases, such substitution process, like hydrolysis, can effectively occur before the
activation via reduction [48].
Having entered clinical trials in 2008, NAMI-A constitutes one success story in the development
of ruthenium anticancer complexes. NAMI-A was first used in a phase I/II study in 32 patients
suffering from an advanced form of non-small cell lung cancer (NSCLC) [49]. The metallodrug was
administered intravenously in combination with gemcitabine, which is regularly used alongside
cisplatin in this type of cancer [44]. Trial results indicated that such combination of NAMI-A and
gemcitabine affected the quality of life of the patients, with side effects including gastrointestinal (GI)
disturbances, neutropenia, and elevated liver enzymes [44]. Although the regimen was deemed to be
“insufficiently effective for further use” [49], this problem may yet have a solution.
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Figure 2. NAMI-A (left) and KP1019/NKP1339 (right) are octahedral Ru(III) pro-drugs, which are
hypothesized to undergo an “activation by reduction” mechanism inside cells to form more active
Ru(II) species.
NAMI-A has a synergistic ability to prevent cell invasion and hinder neo-angiogenesis [50],
making it selective for metastasis rather than fully formed tumors [46]. Compared to cisplatin, NAMI-A
has a wide variety of biological targets, most of which are extracellular rather than DNA-based [44].
One of the main mechanisms through which NAMI-A exerts its anti-angiogenic effects is thought to be
the scavenging of nitric oxide [51]. The nitric oxide synthetase (NOS) pathway stimulates angiogenesis
and endothelial cell migration and also includes VEGF-activated enzymes that catalyze the generation
of NO—a signaling molecule involved in these processes [51,52]. The ruthenium center of NAMI-A,
as well as its albumin adducts, have been proven to bind strongly to NO through displacement of the
DMSO ligand [53]. This reaction is thought to be irreversible in vivo as NO release is unfavorable,
even in the presence of glutathione or other reducing agents. Nitric oxide is a downstream mediator of
VEGF and is implicated in endothelial cell migration [52]. NO scavengers, including NAMI-A, are
reported to cause potent blockade of VEGF-mediated endothelial cell processes related to angiogenesis,
including cell migration [51]. This may be due to NAMI-A’s observed effects on NO, since NAMI-A
has no effect on the phosphorylation status of the downstream proteins, PKB (more commonly known
as Akt) and ERK 12 [54]. NAMI-A does not affect VEGF itself but instead is thought to enable cells
to overcome its inductive properties, supporting the theory that NAMI-A prevents VEGF-mediated
activity through NO scavenging [54].
Another angiogenic process effected by NAMI-A is inhibition of endothelial cellular
proliferation [51], since NO is also a signaling molecule in the mitogen-activated protein kinase (MAPK)
pathway [55]. This pathway includes a cascade of kinases that partake in cellular signaling, which
coordinate various biological processes including cellular proliferation, migration, and survival [56].
After treatment with NAMI-A, cellular proliferation was inhibited for at least 48 h [51], an effect that
could be attributed to NO’s role in the MAPK pathway. Angiogenesis is essential for tumor progression,
since oxygen and nutrients are needed to sustain malignant growth. Angiogenic-inhibition provides
another means of suppressing metastatic development. NAMI-A also reduces the VEGF-dependent
migration of cancerous cells [57]. Inhibition of VEGF activity hence provides a selective mechanism
through which NAMI-A can prevent neo-angiogenesis and the formation of metastases.
NAMI-A has also been reported to act on cells via selective inhibition of the Ca2+-activated
potassium ion channel, KCa3.1 [58]. In most cells, the concentration of potassium ions regulates the
membrane potential, which, in turn, governs cell cycle progression [59]. However, the gene that
encodes KCa3.1 (KCNN4) is overexpressed in many cancer cells [58]. The downstream biological
processes governed by KCa3.1 differ depending on the cell type: (1) proliferation in leukemia and
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lymphoma cells or (2) migration in epithelial and glial cancer cells [58,60]. Such cell-type-dependent
function of the KCa ion channel may explain why the activity of NAMI-A is typically limited in
primary tumors, yet the complex remains potent against leukaemia and metastases. In leukemia
cells, NAMI-A-induced inhibition of KCa3.1 was found to induce G2/M cell cycle arrest, leading to
apoptosis [58]. Ion channels such as KCa3.1 are considered to be indispensable in relation to cellular
migration [61]; hence, NAMI-A is also able to inhibit cell motility. Proliferation and migration of
NSCLC cells is also thought to be dictated by KCa3.1, as more aggressive cancers typically display
up-regulation of this ion channel [62]. NAMI-A-mediated inhibition of KCa3.1 effects malignant cell
migration, either by diminishing or completely preventing the migration of epithelial cancer cells [61].
Another pathway thought to be involved in the mechanism of action of NAMI-A is the ATM/ATR
(Ataxia telangiectasia mutated / RAD3-related) kinase pathway, which is activated after DNA damage
and works to regulate the cellular response [63]. NAMI-A activates both kinases, though appears
more selective for phosphorylation of ATR [54]. The downstream effects include phosphorylation
of the tumor suppressor p53 and kinases CHK1/CHK2, which are normally activated in response
to genetic irregularities to coordinate cell cycle arrest [54]. NAMI-A also increases the expression of
tumors suppressors such as p15INK4b, p21, and p27Kip1—CDK inhibitors that contribute to cell cycle
arrest [54,64].
The anti-metastatic properties of NAMI-A arise from its ability to inhibit certain processes that are
vital for metastatic formation and survival, including the adhesion and migration of cells. In addition
to the mechanisms explained above, NAMI-A can inhibit these processes through protein interference,
such as via α5β1 integrin [65]. Integrins are transmembrane-bound proteins that bind to other cellular
components to facilitate the adhesion and migration of cells. Studies indicate that NAMI-A not only
blocks α5β1 but significantly reduces the number of integrin receptors by modulating the expression
of ITGA5 and ITGB1—the coding genes for the integrin subunits α5 and β1, respectively. This reduces
downstream phosphorylation of focal adhesion kinase (FAK) and both of these processes are thought to
contribute to decreased cellular adherence. Pre-treatment of HCT-116 colon cancer cells with NAMI-A
significantly reduced adherence to Fibronectin and collagen I; an effect that was less apparent in α5β1
integrin-null cells. Notably, the observed effects on cellular adhesion and pFAK occurred in a manner
that was inversely correlated with NAMI-A concentration, further supporting the hypothesis that
lower doses of NAMI-A have greater efficacy [65].
MMP targeting is another anti-metastatic mechanism associated with NAMI-A. It inhibits the
production of MMP-2 and the activity of MMP-2 and MMP-9 [66]. Within the functions of these
MMPs, those of particular interest include chemotaxis and the activation of transforming growth
factor (TGF β1) [67]. Since NAMI-A inhibits endothelial chemotaxis, this may be mediated via MMP
inhibition [66]. The MMPs inhibited by NAMI-A and TGF-β1 partake in a feedback mechanism
as TGF-β1 is also responsible for regulating MMP expression [68], which may explain the effect of
NAMI-A on MMP-2 generation. TGF-β1 is a growth factor that selectively targets cancerous cells,
inducing the epithelial–mesenchymal transition (EMT), invasion and migration; all integral processes
needed for metastatic growth. NAMI-A counteracts this stimulus as it supposedly shares some of the
pathways used by TGF-β1 but leads to opposing outcomes. Therefore, a metastatic response to TGF-β1
is prevented in tumor cells by hindering the processes mentioned above, leaving non-cancerous cell
lines unaffected [69].
6. Case Study: KP1019/NKP1339
Another success story in the development of Ru(III) compounds that have reached clinical
trials is NKP1339, reported by the Keppler group (Figure 2). The original form, KP1019, was
modified to increase its aqueous solubility, generating the sodium salt equivalent, NKP1339 [46].
This Ru(III) complex has some structural similarity to NAMI-A due to its octahedral geometry and
chloride ligands [46]. NKP1339 is a pro-drug and relatively inert compared to NAMI-A, as ligand
loss/exchange does not occur as readily [44,47].
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Both NAMI-A and NKP1339 bind non-covalently with proteins in the blood, likely via
hydrophobic interactions [44,46]. NKP1339 undergoes rapid binding with albumin, so this is an
important factor to consider when the metal complex is administered intravenously. The metal-protein
adduct does account for the low side effect profile documented during the phase I trial of
NKP1339, as the complex remains in its pro-drug form until it undergoes activation by reduction,
after internalization by cells and release from albumin [70]. Albumin binding may also improve the
selective accumulation of NKP1339 through two possible mechanisms: the EPR effect or by binding
to the glycoprotein, gp60 [44]. The former occurs due to leaky vasculature within malignant cells,
resulting in a greater uptake of albumin and other substances, which are then prevented from leaving
by poor lymphatic drainage. In contrast, gp60 is present along the tumor endothelium and allows
receptor-mediated transcytosis of the drug-albumin adduct to occur through to the extracellular
tumor matrix [44]. Adduct formation with blood proteins is more significant for NKP1339 than
NAMI-A since cellular uptake for the latter is limited [44], whereas uptake of NKP1339 is considered
significantly more efficient [71].
Other ruthenium complexes, including RM175 [17], have been previously shown to interact
with DNA through binding to guanine bases after reduction to their active hydrolyzed form [72],
and NKP1339 is no exception. Due to the ability of NKP1339 to accumulate within the nucleus after
activation [47], DNA may be one of the drug’s intracellular targets [46]. During activation, the metal
ion is reduced, and the Ru(II) species is responsible for the DNA-adduct formation. Only weak
adduct signals were emitted when NKP1339 was incubated with oligonucleotides, indicating low
levels of interaction. This may be due, at least in part, to the slow ligand exchange rate of NKP1339,
and a significant proportion of the drug remains intact [47]. In contrast with cisplatin, neither drug
uptake nor genetic mutations, such as those involving p53 and k-ras, are correlated with the efficacy of
NKP1339. This p53-independent mechanism implies that DNA binding is not likely to be the primary
mechanism of action of NKP1339 [70], which may account for the lack of platinum-cross resistance
observed with this Ru(III) complex in pre-clinical studies [73].
NKP1339 induces cell cycle arrest through mechanisms attributed to its redox activity in cancer
cells [46]. Intracellular reactive oxygen species (ROS) concentrations (such as hydroxide radicals
and superoxide) are already elevated in neoplastic cells compared with healthy cells [74] and this
is thought to increase the vulnerability of cancer cells to further ROS fluctuations [75]. As such,
redox-targeting metal complexes have attracted significant attention in recent years, and often
exhibit significant selectivity for cancer cells over healthy cells [74,76–78]. NKP1339 has been shown
to increase the intracellular ROS concentration [79] and upregulate the pro-apoptotic p38 MAPK
pathway [80]. This biological cascade is normally activated in response to cellular stress, such as
cytokines, DNA damage and ROS, and is implicated in cell cycle progression [81]. Activation of this
pathway leads to downstream regulation of gene expression, including those that encode for cytokines,
transcription factors, and cellular receptors [82]. More importantly, this pathway also regulates the
G1/S and G2/M check points within the cell cycle [81]. By generating ROS and altering the cellular
redox balance, NKP1339 induces G2/M cell cycle arrest [46].
Treatment of sensitive cell lines with NKP1339 induced cell death, typically within 20–30 h [70].
Accumulation of ROS prompts the loss of the mitochondrial membrane potential by inducing
membrane permeabilisation, leading to activation of the intrinsic apoptosis pathway [83,84],
which is typically caspase-dependent, and involves the cleavage of the zinc finger protein,
poly-(ADP-ribose)-polymerase (PARP). [70,85] However, in the case of NKP1339, the extent of
mitochondrial membrane depolarization is limited, suggesting another mechanism of apoptosis
may be at work. Caspase-8 was cleaved as part of NKP1339-induced apoptosis [70], a key feature
of the extrinsic apoptosis pathway. Combination treatment with NKP1339 and a caspase-8 inhibitor
increased the extent of apoptosis observed within less responsive cell lines. The researchers deduced
that the majority of apoptosis occurs not by the mitochondrial-intrinsic pathway, but via the extrinsic
pathway [70]. Though mitochondria are a target of NKP1339, the effect of this interaction is limited as
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the majority of apoptotic activity is mediated by either death receptors on the cell surface or via other
extrinsic pathways [86]. Since NKP1339 does not enhance the expression of these death receptors or
their ligands, the Ru(III) complex may act via an alternative extrinsic pathway involving endoplasmic
reticulum (ER) homeostasis [70].
Since the anticancer activity of NKP1339 is predominantly mediated through changes in redox
homeostasis [46], another notable target is the endoplasmic reticulum (ER), which is also influenced
by the cellular redox environment. This organelle controls the maturation, folding, and release of
proteins, and initiates the unfolded protein response (UPR) as part of a feedback system, suspending
the cell cycle either temporarily until the proteins are restored or, permanently, prior to apoptosis [79].
The protein Nrf2 is able to trigger the expression of antioxidant genes to reduce the cell’s exposure to
oxidative stress [87]. After treatment with NKP1339, Nrf2 translocates to the nucleus to commence
its protective activity. This observation may be ROS-mediated and demonstrates that drug-induced
hyper-oxidation is sufficiently substantial to initiate a cellular response. The redox properties of
NKP1339 lead to dysregulation of various other proteins that affect the ER. NKP1339 increases ROS
levels in vitro in colon carcinoma cell lines (HCT116 and SW480), causing upregulation of CHOP
mRNA [79]. The targets of this transcription factor include (1) GADD34, implicated in cell cycle arrest;
(ii) DR5, which promotes cell death through caspase activation and initiation of the extrinsic pathway;
and (3) Ero1α, which leads to ER hyper-oxidation and stimulates cell death [88]. CHOP also reduces
the expression of the anti-apoptotic protein Bcl2, and consequently, excess CHOP generation favors the
induction of apoptosis [79].
Sustained ER stress may result in cellular dysfunction or death [88], so alterations in the UPR
could be exploited for antiproliferative activity. In vitro treatment with NKP1339 was shown to
downregulate various ER-based proteins, including signaling molecules PERK and Ire1α and the
chaperone proteins calnexin and GRP78 [70]. NKP1339 is an effective inhibitor of the last one by
preventing its activation [70,89]. These proteins all have an active role in UPR regulation: calnexin
assists with protein folding, whereas the signaling molecules PERK and Ire1α are two of the main
transmembrane receptors bound to the heat shock protein, GRP78 [79]. When GRP78 senses unfolded
proteins, it simultaneously binds them and liberates the signaling molecules that drive the UPR [79].
GRP78 is often viewed as the “master regulator” of the UPR [89] and functions to protect the cell with
the aim of restoring the ER to its original condition [90]. Downregulation or inhibition of ER proteins
results in a lack of control over protein folding and accumulation of damaged proteins. Drug-induced
ROS generation damages proteins, further enhancing the ER’s exposure to stress [79]. Another
advantage of this mechanism is that GRP78 is associated with chemo-resistance, so inhibition of this
protein may lead to a better prognosis and prevent the occurrence of GRP78-mediated resistance [89].
In vitro use of NKP1339 is also able to increase drug-sensitivity in cells that are already resistant;
a promising indication that drug-resistance might be reversed.
Another reactive oxygen species, nitric oxide, can be scavenged by NKP1339, though its effect on
NO-mediated processes is weak in comparison to NAMI-A [51]. Therefore, there is little evidence to
support its interference with VEGF/NO-stimulated angiogenesis or cell migration [51], explaining
why NKP1339 is more effective against solid tumors than NAMI-A. By unsettling redox homeostasis,
NKP1339 is able to inhibit DNA synthesis, induce G2/M cell cycle arrest and initiate both intrinsic [46]
and extrinsic apoptosis [70]. Owing to its multi-targeting mechanism of action, overexpression of
proteins associated with multi-drug resistance (MRP1, BCRP, LRP, and the transferrin receptor) little
hinders the drug’s efficacy, which also explains the lack of cross-resistance [73,85]. The phase I trial
of NKP1339 was used as a dose-escalation study to assess its use for the treatment of advanced solid
tumors. The study included patient tolerability as well as pharmacodynamic and pharmacokinetic
studies of the drug (Niiki Pharma Inc. and Intezyne Technologies Inc., 2017). The trial (NCT0145297)
was completed in 2016 and was deemed successful [46]. NKP1339 was also shown to be particularly
effective against neuroendocrine tumors (and exhibited limited side effects in trial participants [46,73].
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7. Current Developments in Ruthenium Anticancer Agents and Future Perspectives
The complexes in these four case-studies have paved the way for future research, much of which is
now being completed by not only by well-established researchers but also by internationally recognized
new and upcoming leaders in the field. Pushing the boundaries, new ruthenium anticancer complexes
show a wider diversity of coordination spheres and a vast range of ligands that include, but are not
limited to, extended intercalating aromatic units, polypyridyl rings, fluorescent derivatives, bio-active
molecules, ferrocifen analogues, and carbenes, all of which exploit donor atoms such as C, N, O, S
and P.
Even more interesting is observing the escalation of novel approaches regarding targeting
strategies and MoA involved in the anticancer activity of Ru complexes, all of which are fueled by our
increased understanding of the complexes’ fates at the cellular level. Disruption of protein-protein
interactions, [91] enzymatic inhibition [92,93], and redox modulation [94], as well as chromatin [95]
and histone [96,97] targeting, are only a few examples of cellular events being used as means for
antiproliferative activity, with in-cell catalysis taking advantage of well-established reactions in the
chemistry of materials field [77,78]. Crucially, the understanding of metal anticancer complexes as
efficient multi-targeting agents is starting to have a positive outlook, if not yet for funding bodies,
then at least from an academic perspective. Hence, the attempts to locate a single drug target may
yet develop into the search for a majoritarian cellular event in a field that seems to move at a highly
fast pace.
Such advances and new trends in thought should not forget how far NKP1339, NAMI-A, RM175,
and RAPTA-C have advanced the field, and how critical these complexes have been in the development
of the field. As a community, we may benefit from more closely examining these four compounds to
learn, amongst other things, that small structural changes generate large variations in the MoA at the
cellular level [98]. Although structure activity relationships are not easily established, current and
further developments of analytical and cellular techniques will provide more investigative tools and,
subsequently, a better understanding of cellular behavior. The key for the new generation of anticancer
complexes may well be just round the corner.
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